Promoter Polymorphism (rs3755724, -55C/T) of Tissue Inhibitor of Metalloproteinase 4 (TIMP4) as a Risk Factor for Kawasaki Disease with Coronary Artery Lesions in a Korean Population
暂无分享,去创建一个
S. K. Kim | Sung Wook Kang | Ju Yeon Ban | Joo-Ho Chung | Su Kang Kim | Kyung Leem Yoon | Sungwook Kang | J. Ban | J. Chung | K. Yoon
[1] S Masutani,et al. Circulating Matrix Metalloproteinases and Their Inhibitors in Patients with Kawasaki Disease , 2001, Circulation.
[2] I. Sekine,et al. Elevated serum levels of matrix metalloproteinase‐9 (MMP‐9) in Kawasaki disease , 2001, Clinical and experimental immunology.
[3] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[4] K. Lee,et al. Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population , 2008, Rheumatology International.
[5] F. Baquero-Artigao,et al. Coronary Involvement in Infants with Kawasaki Disease Treated with Intravenous γ-Globulin , 2007, Pediatric Cardiology.
[6] E. Vuorio,et al. Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology , 2006, Histochemistry and Cell Biology.
[7] Youn Jung Kim,et al. Assessment of Relationship between Fyn-related Kinase Gene Polymorphisms and Overweight/Obesity in Korean Population. , 2008, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.
[8] Joan Valls,et al. SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..
[9] R. Kizek,et al. Matrix metalloproteinases. , 2010, Current medicinal chemistry.
[10] Gillian Murphy,et al. Metalloproteinase inhibitors: biological actions and therapeutic opportunities , 2002, Journal of Cell Science.
[11] K. Yabuta,et al. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. , 1990, Clinical immunology and immunopathology.
[12] Walter R Wilson,et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association , 2004, Pediatrics.
[13] S. Crawford,et al. Systemic Arterial Expression of Matrix Metalloproteinases 2 and 9 in Acute Kawasaki Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[14] E. Vuorio,et al. Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA. , 2002, Biochimica et biophysica acta.
[15] L. Rubin,et al. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. , 2006, Archives of pediatrics & adolescent medicine.
[16] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[17] T. Matsuyama,et al. Tissue inhibitor of metalloproteinases‐1 and matrix metalloproteinase‐3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis , 1999, Pediatrics international : official journal of the Japan Pediatric Society.
[18] V. Nerurkar,et al. Elevated Levels of Matrix Metalloproteinase 9 and Tissue Inhibitor of Metalloproteinase 1 during the Acute Phase of Kawasaki Disease , 2003, Clinical Diagnostic Laboratory Immunology.
[19] Toshiro Hara,et al. Genetic Analysis of MMP Gene Polymorphisms in Patients With Kawasaki Disease , 2008, Pediatric Research.